NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of KYTHERA Biopharmaceuticals, Inc. (“Kythera” or the “Company”) (NasdaqGS:KYTH) for potential breaches of fiduciary duties in connection with the sale of the Company to Allergan plc. for approximately $2.1 billion. The Company’s stockholders will only receive approximately $75 per share for each share of Kythera common stock they own. T
| < Prev | Next > |
|---|
